LP
Lupin
LPC.NS·NSEMumbai INFounded 196822,000 employees
Mid CappharmaPublicRespiratoryInfectious Disease
Platform: Generic Resp
Market Cap
$8B
All Drugs
4
Clinical Trials
10
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (LPC.NS)
Loading LPC.NS stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Tezesacituzumab | LPC-9977 | Phase 1/2 | 2 | KRASG12C | Bladder Ca | ||
| LPC-7933 | LPC-7933 | Phase 3 | 4 | IL-17A | CeliacCSU | ||
| LPC-975 | LPC-975 | Phase 2/3 | 2 | TNFα | HNSCCAsthma | ||
| LPC-4508 | LPC-4508 | Phase 1 | 2 | PSMA | ThymomaGA |
SEC Filings & Financial Documents
SEC filings are not available for NSE-listed companies.
Lupin trades on NSE (IN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (7)